• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Top 100 biotech ven­ture in­vestors; Bris­tol My­ers’ IL-12 breakup; Sci­en­tif­ic twist of fate; Track­ing bio­phar­ma ...

3 years ago
Weekly

Bris­tol My­ers, 2sev­en­ty roll out full Abec­ma da­ta in ear­li­er-stage can­cer

3 years ago
R&D
Pharma

Genen­tech to start con­struc­tion on a new man­u­fac­tur­ing fa­cil­i­ty in Cal­i­for­nia

3 years ago
Pharma
Manufacturing

Eli Lil­ly faces an­oth­er age dis­crim­i­na­tion law­suit

3 years ago
Pharma
Law

Pub­li­cis Health Me­dia pres­i­dent An­drea Palmer looks back at 10 years of phar­ma me­dia — and me­te­oric changes

3 years ago
Pharma
Marketing

Vi­sion mat­ters: Bausch + Lomb asks mac­u­lar de­gen­er­a­tion pa­tients to share the sights that in­spire them

3 years ago
Pharma
Marketing

Japan can­cels 140M dose or­der for No­vavax Covid vac­cine amid 'low­er than ex­pect­ed' de­mand

3 years ago
Pharma
FDA+

New SPAC sub­mits plans for $130M IPO, as an­oth­er rais­es $60M

3 years ago
Financing

FDA hands down a par­tial hold for PhI/II tri­al of Blue­print’s CDK2 in­hibitor

3 years ago
FDA+

Aris­tea shut­ters, end­ing hopes of a Pfiz­er buy­out

3 years ago
People
R&D

Eliem CEO ex­its as neu­ro up­start chops head­count, piv­ots to pre­clin­i­cal pro­gram

3 years ago
People
R&D

Oramed to re­view strate­gic al­ter­na­tives, cloud­ing path for­ward for oral in­sulin

3 years ago
Deals
R&D

Still no green light for Phath­om's gas­troin­testi­nal drugs af­ter im­pu­ri­ties found in batch­es

3 years ago
FDA+

FDA ad­vi­sors vote 8-5 in fa­vor of GSK's Jem­per­li tri­al plan for rare rec­tal can­cer

3 years ago
R&D
FDA+

IPO Fri­day: Hy­per­ten­sion drug­mak­er Min­eralys maps out $192M Nas­daq de­but

3 years ago
Financing
Startups

Bay­er, Astel­las gear up for next CEOs; Ex-AM­AG chief Scott My­ers resur­faces at Virid­i­an

3 years ago
Peer Review

In­fla­tion re­bates: CMS lays the ground rules for phar­ma com­pli­ance

3 years ago
Pharma
Law

As­traZeneca CEO Pas­cal So­ri­ot aims for 15 new drug launch­es by 2030

3 years ago
Pharma

Sen­ate Ju­di­cia­ry Com­mit­tee sends five phar­ma-re­lat­ed bills to the floor

3 years ago
Pharma

Ab­b­Vie talks next steps as first Hu­mi­ra com­peti­tor makes it to mar­ket

3 years ago
Pharma

Mid­night in­ter­net search­es? En­do’s new dis­ease aware­ness cam­paign echoes re­al pa­tient con­cerns

3 years ago
Pharma
Marketing

ABPI pres­i­dent steps down over No­vo Nordisk code of prac­tice breach

3 years ago
Pharma

Man­u­fac­tur­ing roundup: Biono­va to ex­pand man­u­fac­tur­ing space; Es­ton­ian man­u­fac­tur­er gets €18M in­vest­ment

3 years ago
Manufacturing

SK Bio­science plans $261M ex­pan­sion in South Ko­rea with new fa­cil­i­ty

3 years ago
R&D
Manufacturing
First page Previous page 377378379380381382383 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times